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Abstract
 
We report the identification of two novel minor histocompatibility antigens (mHAgs), encoded
 
by two separate single nucleotide polymorphisms on a single gene, 
 
BCL2A1
 
, and restricted by
human histocompatibility leukocyte antigen (HLA)-A
 
*
 
2402 (the most common HLA-A allele
in Japanese) and B
 
*
 
4403, respectively. Two cytotoxic T lymphocyte (CTL) clones specific for
these mHAgs were first isolated from two distinct recipients after hematopoietic cell transplan-
tation. Both clones lyse only normal and malignant cells within the hematopoietic lineage. To
localize the gene encoding the mHAgs, two-point linkage analysis was performed on the CTL
lytic patterns of restricting HLA-transfected B lymphoblastoid cell lines obtained from Centre
d’Etude du Polymorphisme Humain. Both CTL clones showed a completely identical lytic
pattern for 4 pedigrees and the gene was localized within a 3.6-cM interval of 15q24.3–25.1
 
region that encodes at least 46 genes. Of those, only 
 
BCL2A1
 
 has been reported to be ex-
pressed in hematopoietic cells and possess three nonsynonymous nucleotide changes. Mini-
gene transfection and epitope reconstitution assays with synthetic peptides identified both
HLA-A
 
*
 
2402– and B
 
*
 
4403-restricted mHAg epitopes to be encoded by distinct polymor-
phisms within 
 
BCL2A1
 
.
Key words: minor histocompatibility antigen • hematopoietic cell transplantation • cytotoxic 
T lymphocyte • graft-versus-leukemia effect • linkage analysis
 
Introduction
 
Minor histocompatibility antigens (mHAgs)
 
* 
 
are MHC-
bound peptides derived from cellular proteins and encoded
by normal polymorphic genes (1–3). Minor antigens with
expression limited to hematopoietic cells represent attractive
candidate targets for immunotherapy to induce favorable
graft-versus-leukemia reactions without causing GVHD af-
ter hematopoietic cell transplantation (HCT; 3–7). Most
mHAgs result from nonsynonymous single nucleotide poly-
morphisms (SNPs). Because many nonsynonymous poly-
morphisms have already been identified through genome
sequencing, it is reasonable to expect that a similarly large
number of mHAgs will eventually be defined. During the
past decade only 12 human mHAgs have been identified at
the molecular level (7–18) and among these, only 4 are en-
coded by autosomal genes (7–10, 17, 18). Most of the
mHAgs so far characterized are restricted by HLA class I
alleles commonly found in Caucasian populations.
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Two Novel Minor Histocompatibility Antigens Encoded by a Single Gene
 
Biochemical approaches using mass spectrometry for
peptides eluted from HLA molecules (8–13) or cDNA ex-
pression cloning (7, 14–16) have been mostly used to iden-
tify human mHAgs. In addition, linkage analysis has been
used to map the chromosomal locations of genes encoding
several mHAgs by using EBV-transformed B cell lines
(LCL) derived from genotypically mapped large pedigrees
such as the Centre d’Etude du Polymorphisme Humain
(CEPH) reference families (19, 20). This approach has be-
come more informative since completion of a draft se-
quence of the human genome (21).
In this study we used linkage analysis as an initial ap-
proach toward identification of mHAgs recognized by two
hematopoietic lineage-specific CTL clones, restricted by
HLA-A
 
*
 
2402 (phenotype frequency: 
 
 
 
65% in Japanese)
and HLA-B44, respectively (unpublished data and 22). Sur-
prisingly, these two CTL clones showed an identical segre-
gation pattern of lysis among a panel of LCL from four
CEPH families but showed distinct patterns among a panel
of LCL from Japanese donors. Using linkage analysis and a
variety of publicly accessible databases, we have identified a
polymorphic gene encoding two mHAg epitopes recog-
nized by these CTL clones. The gene, 
 
BCL2A1
 
, which has
been reported as an inhibitor of apoptosis (23–30), possesses
three SNPs including two that encompass epitopes for the
HLA-A
 
*
 
2402– and B
 
*
 
4403-restricted CTL clones. Our re-
sults not only show the first demonstration of multiple
mHAgs encoded by distinct polymorphic sites on a single
autosomal gene, but also the first successful application of
the linkage analysis to identify a gene encoding mHAgs.
 
Materials and Methods
 
Cell Cultures and Antibodies.
 
HLA-B9.25 pt4403–restricted CTL
clone 3B5/B44 was isolated from day 27 post-HCT PBMC of a
recipient (PT03, 53-yr-old woman) receiving her HLA-identical
brother’s marrow for treatment of chronic myelocytic leukemia
in accelerated phase (22). HLA-A
 
*
 
2402–restricted CTL clone
18B3/A24 was isolated from day 43 post-HCT PBMC of a re-
cipient (PT18, 35-yr-old woman) receiving her HLA-identical
sister’s marrow for treatment of acute myelocytic leukemia in
partial remission. An HLA-B
 
*
 
4403–restricted tyrosinase (SEI-
WRDIDF, amino acid position 192–200; reference 31)-specific
CTL clone was generated by stimulating CD8
 
  
 
cells from healthy
donors with peptide-pulsed antigen presenting cells. These CD8
 
 
 
CTLs were expanded as previously described (32) and frozen un-
til use. LCL lines were derived from the donors and recipients,
and normal volunteers. HLA restriction of the CTL clones had
been determined by lytic activity against a panel of HLA-geno-
typed LCL. All blood or tissue samples were collected after writ-
ten informed consent under a protocol approved by the Institu-
tional Review Board of Aichi Cancer Center. CEPH LCL
registered to the 13th International Histocompatibility Working
Group (provided by P. Martin, Fred Hutchinson Cancer Re-
search Center, Seattle, WA) were retrovirally transduced with re-
stricting HLA cDNA for HLA-A
 
*
 
2402 or B
 
*
 
4403 by a method
previously described (33). Numbers were assigned to each family
member by University of Utah (34). LCL were maintained in
RPMI 1640 medium (Sigma-Aldrich) supplemented with 10%
FCS (Immuno-Biological Laboratory), 2 mM 
 
l
 
-glutamine, 1 mM
sodium pyruvate, and penicillin/streptomycin. mAbs, W6/32
(anti–pan HLA class I), HDR-1 (anti–HLA-DR), and A11.1M
(anti–HLA-A24) were provided by K. Ito (Kurume University,
Fukuoka, Japan).
 
Cytotoxic Assays.
 
Target cells were labeled with 0.1 mCi 
 
51
 
Cr
for 2 h and 10
 
3 
 
target cells/well were mixed with CTL at an E/T
ratio of 10 (unless otherwise indicated) in a standard 4-h cytotox-
icity assay using 96-well round-bottom plates. All assays were
performed at least in duplicate. Cells were treated either with 100
U/ml IFN-
 
  
 
(R&D Systems) or 10 ng/ml TNF-
 
  
 
(Genzyme)
for 48 h as indicated. Percent-specific lysis was calculated as fol-
lows: (experimental cpm 
 
  
 
spontaneous cpm)/(maximum cpm 
 
 
 
spontaneous cpm) 
 
  
 
100. When HLA transfectants were used as
targets, their nontransfectants were also included to exclude po-
tential cross-recognition of allo-HLA molecules. HLA-A24– or
HLA-B44–allospecific CTL were used to confirm the expression
of transduced HLA cDNA.
 
Linkage Analysis and Search for Gene(s) Encoding the mHAgs.
 
CEPH LCL targets that were lysed by the CTL were scored as
expressing the gene encoding the mHAg. Pairwise two-point
linkage analysis was conducted using the MLINK subroutine of
the FASTLINK (v.4.1p) program (35–39) as previously described
(19–21). Cataloged genotypes for the CEPH LCL were obtained
from the CEPH database V9.0 (http://www.cephb.fr/cephdb/;
references 40 and 41). A codominant autosomal gene model was
assumed for the mHAgs trait based on the CTL-defined segrega-
tion pattern in the CEPH families. The population frequency of
the allele(s) encoding mHAgs was estimated at 0.5 and the pene-
trance was set at 0.9 as previously reported (21).
A genetic map of the CEPH families was retrieved from the
Weizmann Institute of Science (http://bioinformatics.weizmann.
ac.il/databases/ceph/). To search for candidate genes encoding the
mHAgs in the region deduced from the linkage analysis, the Uni-
versity of California Santa Cruz (UCSC) genome browser (http://
genome.ucsc.edu; reference 42) and the Map Viewer (http://
www.ncbi.nlm.nih.gov:80/cgi-bin/Entrez/maps.cgi; reference 43)
were used. Tissue distributions of gene expression and known se-
quence polymorphisms of the candidate genes were examined at
the SAGEmap (http://www.ncbi.nlm.nih.gov/SAGE) and the
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/index.html) to re-
fine the candidate genes.
 
Genotyping of CEPH LCL.
 
Primer sequences of selected mi-
crosatellite markers were obtained from the National Center
for Biotechnology Information (NCBI) UniSTS (http://www.
ncbi.nlm.nih.gov/genome/sts/). 10 ng of genomic DNA ex-
tracted from individual LCL was amplified in a total volume of 20
 
 
 
l of 1X buffer (provided) containing 125 
 
 
 
M of each dNTP,
0.5 
 
 
 
M of R110-labeled dUTP (Applied Biosystems), 1.5 mM
MgCl
 
2
 
, 0.5 
 
 
 
M of each primer, and 1 unit AmpliTaq Gold DNA
polymerase (Applied Biosystems). PCR amplification (28 cycles)
was performed on a GeneAmp PCR system 9700 (Applied Bio-
systems) with a predetermined annealing temperature for each
primer pair. The PCR product was then denatured with forma-
mide and the GeneScan 500 TAMRA size standard (Applied
Biosystems) at 95
 
 
 
C for 2 min, and was analyzed with the use of
an ABI model 310 (Applied Biosystems). Fragment sizes and peak
heights were determined automatically by using GeneScan soft-
ware (version 3.1; Applied Biosystems).
 
Sequence Analysis of Candidate Genes.
 
100 ng of genomic
DNA was amplified in a total volume of 25 
 
 
 
l of 1X buffer (pro-
vided) containing 200 
 
 
 
M of each dNTP, 1.0 mM MgSO
 
4
 
, 0.3
 
 
 
M of each primer, and 1 unit KOD-Plus-DNA polymerase
(Toyobo). The PCR conditions were: 30 cycles of 94
 
 
 
C for 15 s,T
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58
 
 
 
C for 20 s, and 68
 
 
 
C for 1 min on a GeneAmp PCR system
9700 (Applied Biosystems). Primer sequences used to amplify
 
BCL2A1
 
 exon 1 were as follows: sense, 5
 
 
 
-CAGTGAGCAT-
TCTCAGCACA-3
 
 
 
; antisense, 5
 
 
 
-CTTATAGGTATCCACA-
TCCG-3
 
 
 
. PCR products were purified and directly sequenced
with the same primers and BigDye Terminator kit (v3.0; Applied
Biosystems) by the use of an ABI PRIZM 3100 (Applied Biosys-
tems).
 
Construction of Minigenes and Truncated Genes for BCL2A1.
 
Minigene expression plasmids encoding the minimal or NH
 
2 
 
ter-
minus–extended polypeptides of the predicted epitopes and their
antigen-negative counterparts were constructed using the
pEAK10 vector (Edge Biosystems) as previously described (10).
The constructs all encoded a Kozak sequence and initiator me-
thionine (CCGCC-ATG) and a stop codon (TAG). Pairs of
sense and antisense oligonucleotides were designed to form co-
hesive ends for HindIII and NotI sites at the 5
 
  
 
and 3
 
  
 
ends after
hybridization, respectively. Expression plasmids encoding the
three allelic forms of the exon 1 of the 
 
BCL2A1
 
 identified by se-
quencing as described above were also constructed by RT-PCR
using primers as follows (HindIII and NotI sites are underlined,
respectively): sense primer, 5
 
 
 
-ATAAGCTTCCACCATGACA-
GACTGTGAATTTGGA)-3
 
 
 
; antisense primer, 5
 
 
 
-ATG-
CGGCCGCTCAGCCTCCGTTTTGCCTTAT-3
 
 
 
. All products
were ligated into HindIII-NotI cut pEAK10 vector and verified
by sequencing. The vectors were then introduced into the donor
LCL by electroporation, followed by selection with 0.7 
 
 
 
g/ml
puromycin (Edge Bio Systems) for 3 d before use in cytotoxic
assays.
 
Epitope Prediction and Epitope Reconstitution Assays.
 
Peptides
spanning the polymorphic amino acid and predicted to bind with
the corresponding HLA molecule by BIMAS software (http://
bimas.dcrt.nih.gov/molbio/hla_bind/; reference 44) and/or SY-
FPEITHI software (http://www.syfpeithi.de; reference 45) were
synthesized by standard methods. 
 
51
 
Cr-labeled mHAg
 
  
 
LCL from
the HCT donors were incubated for 30 min in medium contain-
ing 10-fold serial dilutions of the peptides and 3 
 
 
 
g/ml human
 
 
 
2-microglobulin and then used as target cells in standard cyto-
toxic assays. For introduction of peptides into the cytosol, 7 
 
 
 
10
 
6 
 
LCL were electroporated in 0.4 ml buffer containing graded
concentrations of the peptides at 300 V, 500 
 
 
 
F, and allowed to
rest for 1 h at 37
 
 
 
C before 
 
51
 
Cr labeling.
 
Northern Blot Analysis.
 
The 35-bp complementary oligonu-
cleotide probe of 
 
BCL2A1
 
 exon 1 (5
 
 
 
-CTCCTTATAGG-
TATCCACATCCGGGGCAATTTGCT-3
 
 
 
) was labeled with
 
 
 
-
 
32
 
P-dATP using T4 polynucleotide kinase (Invitrogen) and
purified with a CentriSep column (Princeton Separations). Hu-
man multiple tissue expression array (CLONTECH) was hy-
bridized with the probe for 4 h at 57
 
 
 
C in 10 ml ExpressHyb
(CLONTECH) supplemented with 300 
 
 
 
g sheared salmon tes-
tis DNA (Sigma-Aldrich). The array was washed in 2 
 
  
 
SSC,
1% SDS four times at room temperature for 15 min, and at
57
 
 
 
C for 10 min. The multiple tissue expression array were ex-
posed to BioMax MS film (Kodak) overnight at 
 
 
 
80
 
 
 
C with an
intensifying screen.
 
PCR Analysis of BCL2A1 Gene Expression.
 
cDNA were syn-
thesized from total RNA of bronchial epithelial cells, gastric mu-
cosa, and ileal mucosa. The presence of 
 
BCL2A1
 
, 
 
CD45
 
 (46),
and 
 
GAPDH
 
 messages were detected by PCR using the follow-
ing primers: BCL2A1 sense, 5
 
 
 
-AGCCTACGCACGAAAGT-
GAC-3
 
 
 
; antisense, 5
 
 
 
-TGTTGGCAATCGTTTCCATATC-3
 
 
 
;
CD45 sense, 5
 
 
 
-CTGAAGGAGACCATTGGTGA-3
 
 
 
; antisense
5
 
 -GGTACTGGTACACAGTTCGA-3 ; and GAPDH sense,
5 -GAAGGTGAAGGTCGGAGTC-3 ; antisense, 5 -GAAGA-
TGGTGATGGGATTTC-3 . Amplification products were elec-
trophoresed in 2% agarose and visualized by ethidium bromide
staining.
Results
Characterization of CTL. To determine whether mHAgs
recognized by the CTL clones isolated in this study were
selectively presented by hematopoietic cells, CTL clones
18B3/A24 and 3B5/B44 were tested for lytic activity
against recipient various target cells from hematopoietic and
nonhematopoietic lineage. Both CTLs lysed recipient LCL,
PHA-blasts, and CD40-activated B cells (only for CTL
3B5/B44) but not IFN- –treated dermal nor bone marrow
fibroblasts generated from the corresponding recipients,
whereas these nonhematopoietic cells were lysed by allo
HLA-A24– and B44-specific CTLs, respectively. The addi-
tion of anti-pan HLA class I mAb (and anti–HLA-A24 mAb
for clone 18B3/A24) but not anti–HLA-DR mAb signifi-
Figure 1. Specificity of CTL clones analyzed in standard 51Cr release
assays. (A) HLA-A*2402–restricted CTL 18B3/A24 and (B) HLA-B*4403–
restricted CTL 3B5/B44 were tested against target cells derived from recip-
ient (Rt) or donor (Do) normal tissues at an E/T ratio of 10:1. Recipient
(Rt) dermal fibroblasts, bone marrow fibroblasts, and/or keratinocytes
were incubated with 100 U/ml IFN-  for 48 h before chromium label-
ing. Lysis by (A) allo HLA-A24– and (B) allo HLA-B44–specific CTL
against nonhematopoietic cells are shown as open bars. Antibody block-
ing of the cytolysis was conducted with anti-HLA mAbs (E/T ratios: 1:1
for CTL 18B3/A24 and 10:1 for CTL 3B5/B44). (C) CTL 18B3/A24
and (D) CTL 3B5/B44 were tested against restricting HLA-matched pri-
mary leukemic cells. Frozen cryopreserved leukemic cells incubated with
(solid bar) or without (hatched bar) 10 ng/ml TNF-  for 48 h before as-
say. PHA-stimulated T cell blasts (open bars) were generated from T cells
contaminating in the corresponding leukemic blast. AML, acute myelo-
cytic leukemia identified according to the French-American-British
classification; ALL, acute lymphocytic leukemia; CMMoL, chronic my-
elomonocytic leukemia; CML (BC), chronic myelocytic leukemia in
blast crisis.T
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cantly inhibited lysis of recipient LCL by both CTL clones,
indicating that they were restricted by HLA class I mole-
cules. NK activity-sensitive, HLA-defective K562 cells were
not lysed. (Fig. 1, A and B). They also lysed a fraction of re-
stricting HLA-matched primary leukemic cells from other
patients, and lysis of these cells increased after TNF-  treat-
ment (Fig. 1, C and D). These results suggest that the
mHAgs are selectively expressed by hematopoietic cells.
The population frequency that expresses the mHAg-
encoding genes was estimated by evaluating the lytic activity
of each CTL clone against a panel of HLA-B*4403–trans-
duced LCL from HLA-A*2402  Japanese volunteers. CTL
18B3/A24 lysed 11 of 14 (79%) targets, whereas CTL
3B5/B44 lysed 7 of 14 targets (50%; not depicted), suggest-
ing that the two mHAgs are defined by distinct SNPs.
Determination of mHAg Phenotype of CEPH Families by
Cytotoxic Assays. To determine which CEPH families
were informative for linkage analysis, LCL from parental in-
dividuals of 12 CEPH families were transduced with restrict-
ing HLA alleles and screened. Families were selected for fur-
ther analysis if one parent was positive and the other was
negative because an informative segregation can be expected
unless the proband is homozygous. The two CTL clones un-
expectedly showed the identical lytic patterns (not depicted).
All available LCL from the selected four CEPH families
were then transduced in the same way and tested as targets
with CTL 18B3/A24 and 3B5/B44 in standard 51Cr release
assays. The two CTL clones had identical lytic patterns
when tested against these four families (only the results
with CTL 18B3/A24 is shown in Fig. 2 A). These data
suggest that the polymorphic gene(s) controlling the ex-
pression of the two mHAgs are closely located on a narrow
chromosomal region or encoded by a single gene. It is un-
likely that a single SNP encodes both mHAgs, however,
because lytic patterns for the two clones against a panel
LCL from Japanese donors were not identical.
The Gene(s) Encoding the mHAgs Are Mapped to Chromo-
some 15q24.3–25.1. Two-point linkage analysis was con-
ducted in the four families: one family, 1362, was highly
mapped ( 10,000 markers/whole genome) whereas three
families, 1346, 1349, and 1408, were mapped at lower den-
sity ( 4,000 markers). Nevertheless, only one cluster of
marker loci was found to be associated with the mHAg
phenotype (Fig. 2 B). The markers around D15S96 on
chromosome 15q24.3–25.1 gave LOD scores of 3 or
higher, although most of the LOD scores were generated
from family 1362 because the density of mapped markers
was sparse within the region of interest in the remaining
three families (Fig. 2 C).
By retrieving the available genotypes of all the individu-
als in the four families located around the marker D15S96
from the CEPH database (40, 41) and the Weizmann Insti-
Figure 2. Linkage analysis. (A) The results of phenotyp-
ing for the pedigrees of CEPH families. Filled symbols ( ,
males;  , females) represent individuals scored as positive
in the 18B3/A24 cytotoxic assay and open symbols ( ,
males;  , females) represent individuals scored as negative.
Shaded symbols represent individuals from whom no LCL
was available. Numbers above or below the symbols were
assigned to each family member by the University of Utah
(reference 34). The identical lysis pattern was also observed
with CTL 3B5/B44. (B) Distribution of the LOD scores
for each genetic marker on whole chromosomes are shown
serially starting from the proximal end of chromosome 1.
(C) Genetic map of distal chromosome 15q showing rela-
tive positions of marker loci, oriented with the 15q telo-
mere at the bottom of the figure. LOD scores for each
marker are indicated to the right of each marker. Because
families other than 1362 have not been mapped exten-
sively, families used to calculate the LOD scores are indi-
cated in the parentheses. The location of the marker
D15S96 that gave the highest LOD score has not been
well defined, therefore its potential region on the map is
indicated as a dashed line.T
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tute of Science, it was possible to identify several informa-
tive individuals who had recombinant haplotypes. After
genotyping these individuals by using microsatellite mark-
ers adjacent to D15S96, the recombinant haplotypes carry-
ing the mHAgs allele could be characterized (Fig. 3). The
genetic region controlling the mHAg expression was esti-
mated by comparing the recombinant haplotypes of the
offspring with the mHAg phenotypes detected by CTL as-
says. For example, the father in family 1408 possessed the
mHAg  allele (Fig. 2 A). The recombinant paternal haplo-
types inherited by individual 1694 implies that the gene(s)
encoding the mHAg expression should lie telomeric to the
marker D15S1023/AFMb347wa9. Similarly, the recombi-
nant paternal haplotypes inherited by individual 1038 in
family 1408 implies that the gene(s) should lie centromeric
to the marker D15S154/AFM211xh2. Collectively these
data suggest that the gene(s) must be encoded between
these two markers, a distance corresponding to 3.6 cM on
the Généthon map (47) or 5.5 Mbp.
Identification of Candidate Polymorphic Gene(s). We set
aside the possibility that the mHAgs detectable by CTLs
18B3/A24 and 3B5/B44 are formed by either SNPs lo-
cated in a promoter region, intronic sequence, or congeni-
tal gene defect. Thus, to narrow the candidate gene(s) that
might encode the mHAgs, we made the following assump-
tions: (a) Nonamer or decamer amino acid sequences span-
ning the nonsynonymous change with binding motifs for
HLA-A*2402 and B*4403 should be found in the gene(s),
(b) Two distinct nonsynonymous amino acid changes
might be coded in the same gene or in closely linked genes
near 15q24.3–25.1, and (c) The gene(s) are expressed only
in cells of hematopoietic lineage, based on the tissue-spe-
cific pattern of lysis with the CTLs.
A search of the UCSC genome browser (42) and the
Map Viewer (43) identified at least 46 genes that have been
mapped to the region between the markers D15S1023/
AFMb347wa9 and D15S154/AFM211xh2. Nine of these
genes contained at least one nonsynonymous SNP (Table
I). All nine potentially encode nonamer or decamer pep-
tides spanning the nonsynonymous SNP with a predicted
binding score of 1.0 or higher according to BIMAS soft-
ware (44). On the other hand, only 2 of the 46 genes in the
region of interest (BCL2A1 and HSPC073) are known to
have expression limited to hematopoietic cells (and several
solid tumor cells for BCL2A1), although data for some of
the 9 candidate genes found in the SAGEmap database re-
main incomplete. BCL2A1 contained seven peptide motifs
for HLA-A*2402 and six for HLA-B*4403 spanning one of
three SNPs, whereas HSPC073 had no reported SNPs so
far. Taken together, only BCL2A1 fulfilled our initial as-
sumptions. Indeed, BCL2A1 (formally, BCL2-related pro-
tein A1) is known as a member of anti-apoptotic BCL2
family (25) and is up-regulated by TNF-  (26, 29, 30),
which is consistent with the increased lysis of primary leu-
kemic cells (Fig. 1, C and D).
Two Nonsynonymous SNPs in the BCL2A1 Gene Deter-
mine CTL Recognition. Because CTLs 18B3/A24 and
3B5/B44 demonstrated a different pattern of lysis in LCL
from Japanese donors as described above, we analyzed the
BCL2A1 exon 1 sequence (420 bp in length, Fig. 4) of six
HLA-B*4403–transduced LCL from HLA-A*2402  Japa-
nese normal volunteers used in the CTL assay (see above)
and four LCL from the recipients, PT18 and PT03 and
their donors, and compared the results with the cDNA se-
quence identified in the GenBank database (sequence data
are available from GenBank/EMBL/DDBJ under accession
no. NM004049). As shown in Table II, susceptibility to
CTL 18B3/A24 correlated completely with the presence
of adenosine at nucleotide position 56 and guanosine at nu-
cleotide position 116, whereas susceptibility to CTL 3B5/
B44 correlated completely with the presence of adenosine
at nucleotide position 245. These results suggest that the
mHAg epitope recognized by CTL 18B3/A24 is encoded
by a region spanning either nucleotide position 56 or 116,
whereas the one recognized by CTL 3B5/B44 is encoded
by the region spanning nucleotide position 245.
To confirm these results, we constructed mammalian ex-
pression plasmids encoding the three identified allelic forms
of exon 1 (i.e., designated as A-G-A, A-G-G, and G-T-G;
nucleotides shown as a single alphabet) and transfected into
Figure 3. The gene(s) encoding the mHAgs defined by
CTLs 18B3/A24 and 3B5/B44 are mapped to a 3.6-cM
interval spanned by the markers D15S1023/AFMb347wa9
and D15S154/AFM211xh2. The parental probands and
their informative offspring who had inherited recombinant
haplotypes between the markers D15S965/AFMa139zb1
and D15S158/AFM234vf12 correspond to the region
shown in Fig. 2 C. Genotypes of the requisite markers for
family 1408 that were not available at the CEPH database
(references 40 and 41) were examined in our laboratory.
The genotypes are arranged by haplotype, with the pater-
nally and maternally inherited haplotypes on the left and
right, respectively. The appearance of a 0 in any haplotype
indicates that no genotype was available and was not fur-
ther examined. The susceptibility of individual LCL to the
two CTL clones is indicated at the bottom of the figure.
The parental haplotypes carrying gene(s) controlling mHAgs that were deduced by the segregation pattern (Fig. 2 A) in each family are shown in shaded
blocks and their “antigen-negative” counterparts are shown in hatched blocks. Open blocks indicate regions that cannot be assigned to a parental haplo-
type. Thus, recombinant haplotypes are those composed of two blocks with different symbols, and the recombination event is thought to have occurred
between the markers in different blocks.T
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1494 Two Novel Minor Histocompatibility Antigens Encoded by a Single Gene
the donor LCL corresponding to each CTL. CTL 18B3/
A24 lysed the donor LCL transduced with plasmid encod-
ing either A-G-A or A-G-G, whereas CTL 3B5/B44 lysed
the donor LCL transduced only with plasmid encoding
A-G-A (Fig. 5, A and B). Therefore, we conclude that
SNPs in BCL2A1 gene encode mHAgs recognized by
18B3/A24 and 3B5/B44.
Identification of HLA-A*2402–restricted mHAg Epitope.
Because cytotoxic activity of CTL 18B3/A24 was con-
trolled by the SNPs either at nucleotide position 56
(amino acid position 19) or 115 (amino acid position 39),
we searched for amino acid sequences spanning these
SNPs using BIMAS software (44). Because most de-
scribed HLA-A*2402 binding peptides contain nine
amino acid residues (45), we examined two nonamer
peptides, starting at amino acid positions 13 and 15
(AQDYLQYVL, DYLQYVLQI; polymorphic residue
underlined) from mHAg  allele (Fig. 4). Their predicted
binding scores were 4.8 and 75, respectively. The
mHAg  allele found in the donor encodes Cys(C) instead
of Tyr(Y) at position 19. Binding scores for the C-con-
taining peptide were similar to those for the Y-containing
peptide. No nonamer HLA-A*2402 binding peptide mo-
tifs spanning amino acid position 39 were predicted. We
constructed four minigenes encoding nonamer peptides
with sequences predicted as above, and tested the donor
LCL transfected with each of these minigenes in 51Cr-
releasing assays with CTL 18B3/A24 (Fig. 5 B). Only the
donor LCL carrying a minigene encoding DYLQYVLQI
was recognized by the CTL. Thus, we next synthesized
two nonamer peptides, DYLQYVLQI and DYLQCV-
LQI, and tested the cytotoxicity of CTL 18B3/A24 on
the donor LCL by pulsing with graded amounts of each
peptide. The titration of peptide DYLQYVLQI recog-
nized by CTL 18B3/A24 gave half-maximal lysis at a
concentration of 20 pM, whereas peptide DYLQCVLQI
failed to sensitize the donor LCL at any of the concentra-
tions tested (Fig. 5 D). Thus, DYLQYVLQI defines the
HLA-A*2402–restricted 18B3/A24 epitope, and we des-
ignated it BCL2A1/A24Y. An MHC stabilization assay
(48) using HLA-A*2402–transfected T2 cells pulsed with
either of the two peptides demonstrated a closely similar
increase in fluorescence intensity when stained with anti–
HLA-A24 mAb (unpublished data), suggesting that both
Table I. Genes with at Least One Nonsynonymous Coding SNP Mapped between the Markers D15S1023/AFMb347wa9
and D15S154/AFM211xh2
Genea
Hematopoietic
lineage restrictionb
Nonsynonymous
coding SNPsc
Peptide motifs for
HLA-A*2402d
Peptide motifs for
HLA-B*4403d
BCL2A1 Yes 3 7 6
MTHFS No 1 0 1
FLJ21140 No 1 4 2
BG1 No 1 2 3
ZNF291 No 2 14 5
ETFA No 2 11 10
AWP1 No 2 6 5
PSMA4 No 1 0 2
CHRNA5 No 1 4 1
aGenes were retrieved from the RefSeq database based on the assembled human genome sequence databases available at http://genome.ucsc.edu
(reference 42) and the NCBI Map Viewer (references 43).
bTissue-specific gene expression was searched by SAGEmap.
cThe number of nonsynonymous coding SNPs was searched by dbSNP.
dAmino acid sequences of the genes were analyzed for nonamer or decamer peptides capable of binding to HLA-A*2402 and HLA-B*4403 using
BIMAS software (reference 44), and only peptides with a binding score of 1.0 or higher were counted.
Figure 4. Nucleotide and deduced amino acid sequences of the human
BCL2A1 exon 1 cDNA. The deduced amino acid sequence is shown in
one-letter designation below the nucleotide sequence. All three reported
nonsynonymous SNPs (positions 56, 116, and 245) and the correspond-
ing amino acid residues (positions 19, 39, and 82) are indicated in bold
type. The sequence corresponding to the CTLs 18B3/A24- and 3B5/
B44-defined peptides is boxed.T
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peptides could be presented on HLA-A*2402. Immuno-
genicity of DYLQCVLQI (BCL2A1/A24C) in donor re-
cipient pairs with the reciprocal allele combination has
not been determined.
Identification of HLA-B*4403–restricted mHAg Epitope.
The preferred HLA-B*4403 anchor residues are Glu(E) at
position 2 and a Phe(F), Tyr(Y), or Trp(W) at position 9 or
10, and nearly half of the B*4403 peptides contain 10
Table II. Correlation of BCL2A1 Sequence Polymorphisms with Susceptibility to the CTLs
HLA-A*2402 and HLA-B*4403  LCLa,b
PT18 PT18 PT03 PT03 UR1 UR2 UR3 UR4 UR5 UR6
Rt Do Rt Do
Cytolysis by clones
18B3/A24           
3B5/B44           
Detected nucleotide polymorphismsc
56 G/A G A G/A G/A G/A G/A A G G/A
116 T/G T G T/G T/G T/G T/G G T T/G
245 G/A G G/A G G G G/A A G G
aHLA-B*4403  LCL were transduced with the HLA-B*4403 cDNA.
bRt, recipient; Do, donor; UR, unrelated.
cNucleotide positions are shown starting at translation initiation codon.
Figure 5. The two mHAg epitopes defined by CTLs
18B3/A24 and 3B5/B44 are encoded by a single gene
BCL2A1. Mammalian expression plasmids encoding three
allelic forms of the BCL2A1 exon 1 identified in the cor-
relation study (refer to Table II) were transfected into (A)
PT18 donor (Do) LCL and (B) PT03 donor LCL and their
susceptibility to (A) CTL 18B3/A24 and (B) CTL 3B5/
B44 was tested. Individual recipient (Rt) LCL was used as
positive control. (C) Identification of CTL 18B3/A24-
defined epitope. Susceptibility of PT18 donor LCL trans-
duced with minigene constructs encoding BCL2A1 poly-
morphic peptides spanning amino acid 19 was assessed in a
standard 51Cr release assay. Two pairs of nonamer peptides
starting at amino acid positions 13 and 15 with binding
score of 1.0 or higher were predicted by BIMAS software
(reference 44). Polymorphic amino acids (Y or C) are un-
derlined. CTL lysis of PT18 recipient (Rt) and donor (Do)
is also shown. (D) mHAg epitope reconstitution with syn-
thetic nonamer peptides with amino acid sequence starting
at position 15. (E) Identification of CTL 3B5/B44-defined
epitope. Susceptibility of PT03 donor LCL transduced
with minigene constructs encoding two BCL2A1 poly-
morphic peptides (KEFEDDIINW and KEFEDGIINW,
refer to Table III) was tested at various E/T ratio. Poly-
morphic amino acids (D or G) are underlined. CTL lysis of
PT03 recipient (Rt) and donor (Do) is also shown. (F)
mHAg epitope reconstitution with synthetic decamer pep-
tides. Besides conventional peptide pulsing, direct delivery
of synthetic peptides into the cytosol by electroporation
was used (EP). As negative control, HLA-B*4403–restricted
tyrosinase epitope (SEIWRDIDF; reference 31) was used.
(G) An HLA-B*4403–restricted tyrosinase epitope (SEI-
WRDIDF)-specific CTL was generated from a normal do-
nor and tested against autologous (Auto) LCL, autologous
LCL transduced with minigene constructs encoding SEI-
WRDIDF, or HLA-B*4403–transduced Mel-501 mela-
noma cell line with intrinsic expression of tyrosinase. (H)
Reconstitution assay for synthetic peptides using the ty-
rosinase-specific CTL.T
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amino acid residues (45, 49). Because three Glu(E) residues
are close to the known polymorphic amino acid at position
82 of the BCL2A1 protein, we listed all nonamer or
decamer peptides spanning the position 82 and constructed
minigenes encoding peptides with a binding score of 1.0 or
higher by BIMAS software (44). Lysis was observed only
against PT03 donor LCL transfected with a minigene en-
coding a decamer peptide starting at amino acid position 77
and containing Asp(D) residue (KEFEDDIINW; Table III
and Fig. 5 E). Regardless of a D or G residue at position 82,
this decamer had the highest binding score not only by BI-
MAS software but also by SYFPEITHI software. To verify
that synthetic peptide KEFEDDIINW can sensitize the
PT03 donor LCL, we performed an epitope reconstitution
assay. Half-maximal lysis was observed with 400 nM for
peptide KEFEDDIINW, whereas peptide KEFEDGIINW
or irrelevant HLA-B*4403–restricted tyrosinase epitope
(SEIWRDIDF; reference 31) failed to sensitize the donor
LCL even at 100  M. When peptide KEFEDDIINW was
introduced directly into the cytosol by electroporation, 10-
fold less concentration was required to obtain the half-max-
imal lysis (Fig. 5 F). We also tested a CTL clone specific for
SEIWRDIDF derived from tyrosinase. This CTL clone
generated from a normal donor efficiently lysed not only
autologous LCL transduced with minigene constructs en-
coding SEIWRDIDF, but also HLA-B*4403–transfected
Mel-501, a melanoma cell line with intrinsic expression of
tyrosinase. The concentration of the peptide SEIWRDIDF
needed for half-maximal lysis was 1  M, suggesting that
HLA-B*4403 might not present exogenously pulsed pep-
tides as efficiently as other HLA alleles. Taken together,
KEFEDDIINW defines the HLA-B*4403–restricted 3B5/
B44 epitope and was designated as BCL2A1/B44D.
Selective Expression of the BCL2A1 Gene in Human He-
matopoietic Tissues. To determine the relative levels of ex-
pression of BCL2A1 in a more comprehensive manner, an
RNA dot blot analysis was performed (Fig. 6 A). Array
analysis indicated that the expression of BCL2A1 was
strongly expressed by peripheral blood leukocytes, bone
marrow, and to lesser extent, by lymph node and spleen. A
weak signal was also detected in lung and gastrointestinal
tract, but as shown in Fig. 6 B, an RT-PCR analysis
showed parallel expression of BCL2A1 and CD45 mes-
sages in cultured bronchial epithelial cells (both negative),
gastric glands (both weakly positive), and intestinal glands
(both moderately positive), suggesting that BCL2A1 signal
originated from contaminated hematopoietic cells in these
tissues. No expression was detected in other tissues.
Discussion
In this study, we identified a gene encoding two
mHAgs by using linkage analysis. The feasibility of using
linkage analysis as an initial approach to identify a single
gene was recently suggested by analysis of the HA-8
mHAg encoded by KIAA0020 (21). To the best of our
knowledge, our study is the first successful prospective
identification of novel mHAgs by linkage analysis. The
key to success with this approach depends on the accuracy
and completeness of the available genome sequence data-
bases. There were some gaps between map contigs in the
UCSC Genome database (42; December 2001 Freeze),
but the gaps decreased in a later version (April 2002
Freeze). Moreover, the order and chromosomal location
of segments comprising of several genes in the region of
interest changed dramatically between the two versions
and in fact, the marker D15S1023/AFMb347wa9 used to
define the centromeric border was not included in the
former version. Although our strategy to select candidate
genes based on their tissue-specific expression and the
presence of HLA-A*2402 or HLA-B*4403 binding pep-
tides with nonsynonymous SNPs has successfully led to
Table III. Minigene Sequences Encoding Nonamer or Decamer Peptides Spanning the BCL2A1 Polymorphic Regions (BIMAS Score of 1.0 or 
Higher) and Recognition of Their Transfectants by CTL 3B5/B44a
Position Peptide sequenceb Length
BIMAS 
scorec
SYFPEITHI 
scored
Specific
lysis (percent)e
75–83 MEKEFEDDI 9 4.0 18 3
75–84 MEKEFEDDII 10 4.0 18 0
77–85 KEFEDDIIN 9 1.2 14 1
77–86 KEFEDDIINW 10 12.0 27 66
77–86 KEFEDGIINW 10 12.0 27 3
81–89 DDIINWGRI 9 11.25 12  1
81–90 DDIINWGRIV 10 11.25 4 2
aPT03 donor LCL were transfected with minigene constructs encoding the BCL2A1 polymorphic peptides listed.
bPolymorphic amino acids are underlined.
cBinding score to HLA-B*4403 was predicted by BIMAS software (reference 44).
dBinding scores to HLA-B*4402 predicted by SYFPEITHI software (reference 45) are indicated because CTL 3B5/B44 could lyse targets in the
context of HLA-B*4402 as well as HLA-B*4403.
ePercent specific lysis by CTL 3B5/B44 performed at the E/T ratio of 10:1.T
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the identification of mHAgs encoded by the BCL2A1
gene, incomplete database information still poses a chal-
lenge for the use of linkage analysis in identifying genes
that potentially encode mHAg.
Theoretically, any genetic polymorphism that changes
cell surface expression of the self-peptides directly or indi-
rectly can be recognized as mHAg between recipients and
their donors in the setting of allogeneic HCT (2). There
are two major mechanisms involved: recognition by spe-
cific T cells and presentation by MHC molecules. In hu-
mans, HLA-B7–restricted HY (12), HLA-A1–restricted
HY (13), and HB-1 (7, 18) mHAgs are examples where the
fine specificity of a TCR distinguishes two alleles, each en-
coding peptides that can be presented by the relevant HLA
molecule. Peptide polymorphisms can affect several steps
involved in antigen processing, including binding affinity
to the relevant HLA molecules, as demonstrated for HA-1
(8), translocation efficiency through transporter associated
with antigen processing, as demonstrated for HA-8 (10),
and proteasomal cleavage or another undetermined mecha-
nism, as demonstrated for HA-2 (9).
In the case of the mHAg BCL2A1/A24, mHAg  donor
cells pulsed with BCL2A1/A24C peptide were not recog-
nized by the CTL, even though the BCL2A24C  and
BCL2A1/A24Y  peptides both bind efficiently to HLA-
A*2402. These observations indicate that the BCL2A1/
A24C/Y polymorphism affects a TCR contact residue. We
cannot exclude the possibility that the BCL2A1/A24C pep-
tide is not produced properly or is destroyed by proteaso-
mal cleavage. The two algorithms available for prediction
of proteasomal cleavages (PAPROC, references 50, 51;
NetChop, reference 52) indicate that the COOH terminus
is not properly formed by proteasomes when the polymor-
phic residue is Cys(C), but not Tyr(Y), which suggests that
the BCL2A1/A24C peptide might not be produced endog-
enously. Attempts to induce BCL2A1/A24C-specific CTL
from HCT recipients are currently in progress.
Results in the epitope reconstitution assays showed that
an unusually high peptide concentration was required for
sensitization with BCL2A1/B44D, but the genetic data and
minigene experiments strongly support the conclusion that
the identified sequence is the epitope for clone 3B5/B44.
The consensus peptide binding motif for HLA-B*4403
demonstrates a predominance for Glu(E) at position 2, and
Tyr(Y) or Phe(F) at position 9 or 10 (45, 49). BCL2A1/
B44D/G peptide contains a Glu(E) at position 2 but Try(W)
at position 10, which is not a preferred residue (44). Inter-
estingly, HB-1H/Y, a minor antigen that is also restricted by
HLA-B*4403, and BCL2A1/B44D/G have identical residues
at these positions and the binding scores predicted by BI-
MAS software (18.0 vs. 12.0) and SYFPEITHI software
(25 vs. 27) are similar for the four peptides. The HB-1H
peptide concentration required to obtain the half-maximal
lysis is  10 nM (7, 18), nearly 40-fold lower than with the
BCL2A1/B44D  peptide ( 400 nM). Other previously
identified HLA-B*4403–restricted epitopes also require
peptide concentrations of 1–100 nM with one exception:
tyrosinase (100 nM; reference 31), MAGE3 (40–100 nM;
reference 53), and MUM1 (1 nM; reference 54) versus
EBNA3C ( 1 pM; reference 55). However, direct deliv-
ery of peptide into the cytosol by electroporation decreased
the required peptide concentration by 10-fold. Moreover,
nearly 1  M peptide was necessary to sensitize target LCL
for a tyrosinase-specific CTL that is considered to have a
high affinity T cell receptor because it could lyse a mela-
noma cell line. A peptide-induced CTL clone specific for
HB-1 mHAg also required 1  M peptide (Dolstra, H.,
personal communication). Finally, the unique property of
HLA-B*44 is supported by the fact that HLA-B*44 tet-
ramer would not refold as posted in The National Institutes
of Health (NIH) Tetramer Facility web page (http://
www.emory.edu/WHSC/TETRAMER/faq.html). These
facts suggest that HLA-B44 might not present exogenously
pulsed peptides as efficiently as other HLA alleles, and only
peptides with specific characteristics, such as loading in the
ER, might be presented by this molecule.
Immunotherapy with BCL2A1-specific T cells would
not be expected to cause GVHD after allogeneic HCT,
once the normal hematopoietic cells expressing this gene
Figure 6. (A) RNA dot blot analysis of BCL2A1 gene expression in 68
distinct human tissues and 8 tumor cell lines. Tissue sources for the RNA
are indicated below the blot. (B) BCL2A1 and CD45 expression of
PBMC, cultured bronchial epithelial cell line, and isolated glands from
stomach and intestine. Gene-specific RT-PCR was performed with a pre-
determined amount of each cDNA based on the PCR results for GAPDH.T
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in the recipient have been eliminated by the transplant
procedure. It is conceivable, however, that normal nonhe-
matopoietic cells might express BCL2A1 during the in-
tense cytokine production that occurs during acute
GVHD (56), potentially making these cells susceptible to
attack by BCL2A1-specific CTL. Preliminary results
showed that the incidence rates of acute or chronic
GVHD were not increased among 49 patients with
BCL2A1/A24 disparity compared with 158 recipients
with no BCL2A1/A24 disparity. In addition, both recipi-
ents with advanced leukemia from whom the two clones
were generated have remained in complete remission for
more than a year after HCT without acute GVHD, al-
though PT03 has mild oral chronic GVHD. Further test-
ing will be needed to determine definitively whether
BCL2A1 mismatching in a transplant recipient is associ-
ated with an increased risk of GVHD.
To date, only a limited number of human mHAgs have
been fully characterized (7–18) and most of these are re-
stricted by HLA-A*0201, HLA-A*0101, HLA-A*0301,
HLA-B*0702, and HLA-B*0801. The identification of
mHAgs restricted by HLA alleles that are common in cer-
tain ethnic groups such as the Asian population has not
been reported. HLA-A*2402 is very common in Japanese
(phenotype frequency  65%) and other Asian populations.
The identification of HLA-A*2402-restricted mHAg may
provide many patients in this ethnic group with the oppor-
tunity to have hematological malignancies treated by im-
munotherapy. In fact, we have already succeeded in gener-
ating BCL2A1/A24Y-specific CTL from PBMC of the
recipient from whom CTL 18B3/A24 was cloned by stim-
ulation with peptide-pulsed, donor-derived CD40-acti-
vated B cells. An HLA-A24 tetramer incorporating
BCL2A1/A24Y peptide has also been constructed and has
been used to identify the presence of tetramer-positive
CD8  cells (0.2% of CD8  cells) among recipient PBMC
on day 43 after HCT and to monitor the rapid expansion
of mHAg-specific CD8  cells after ex vivo stimulation (un-
published data). Because of the potential application to im-
munotherapy for various types of recurrent malignancies
after allogeneic HCT, we are seeking to identify other
HLA-restricted mHAg epitopes in BCL2A1.
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